| Cardiomyopathy with restrictive physiology in sickle cell disease O Niss, CT Quinn, A Lane, J Daily, PR Khoury, N Bakeer, TR Kimball, ... JACC: Cardiovascular imaging 9 (3), 243-252, 2016 | 135 | 2016 |
| Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia O Niss, R Fleck, F Makue, T Alsaied, P Desai, JA Towbin, P Malik, ... Blood, The Journal of the American Society of Hematology 130 (2), 205-213, 2017 | 103 | 2017 |
| Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology N Bakeer, J James, S Roy, J Wansapura, SK Shanmukhappa, JN Lorenz, ... Proceedings of the National Academy of Sciences 113 (35), E5182-E5191, 2016 | 78 | 2016 |
| Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis O Niss, S Chonat, N Dagaonkar, MO Almansoori, K Kerr, ZR Rogers, ... Blood Cells, Molecules, and Diseases 61, 4-9, 2016 | 75 | 2016 |
| Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia PT McGann, O Niss, M Dong, A Marahatta, TA Howard, T Mizuno, A Lane, ... American journal of hematology 94 (8), 871-879, 2019 | 59 | 2019 |
| Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia CT Quinn, EP Smith, S Arbabi, PK Khera, CJ Lindsell, O Niss, CH Joiner, ... American journal of hematology 91 (12), 1195-1201, 2016 | 55 | 2016 |
| The Spectrum of SPTA1-Associated Hereditary Spherocytosis S Chonat, M Risinger, H Sakthivel, O Niss, JA Rothman, L Hsieh, ... Frontiers in physiology 10, 815, 2019 | 45 | 2019 |
| Losartan for the nephropathy of sickle cell anemia: A phase‐2, multicenter trial CT Quinn, SL Saraf, VR Gordeuk, CD Fitzhugh, SE Creary, P Bodas, ... American journal of hematology 92 (9), E520-E528, 2017 | 44 | 2017 |
| Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study O Niss, A Lane, MR Asnani, ME Yee, A Raj, S Creary, C Fitzhugh, ... Blood advances 4 (7), 1501-1511, 2020 | 42 | 2020 |
| Gene therapy for sickle cell anemia using a modified gamma globin lentivirus vector and reduced intensity conditioning transplant shows promising correction of the disease … P Malik, M Grimley, CT Quinn, A Shova, L Courtney, C Lutzko, TA Kalfa, ... Blood 132, 1021, 2018 | 32 | 2018 |
| IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome O Niss, A Sholl, JJ Bleesing, DA Hildeman Journal of Allergy and Clinical Immunology 135 (3), 762-770, 2015 | 23 | 2015 |
| Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics‐guided dosing can produce sustained and nearly pancellular expression of fetal … CT Quinn, O Niss, M Dong, A Pfeiffer, J Korpik, M Reynaud, H Bonar, ... British journal of haematology 194 (3), 617-625, 2021 | 20 | 2021 |
| Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia T Alsaied, O Niss, AW Powell, RJ Fleck, JF Cnota, C Chin, P Malik, ... Pediatric blood & cancer 65 (8), e27113, 2018 | 20 | 2018 |
| A reappraisal of the mechanisms underlying the cardiac complications of sickle cell anemia P Rai, O Niss, P Malik Pediatric Blood & Cancer 64 (11), e26607, 2017 | 17 | 2017 |
| Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity T Alsaied, O Niss, JT Tretter, AW Powell, C Chin, RJ Fleck, JF Cnota, ... Scientific reports 10 (1), 1767, 2020 | 16 | 2020 |
| Safety and efficacy of Aru-1801 in patients with sickle cell disease: early results from the phase 1/2 momentum study of a modified gamma globin gene therapy and reduced … M Grimley, M Asnani, A Shrestha, S Felker, C Lutzko, PI Arumugam, ... Blood 138, 3970, 2021 | 15 | 2021 |
| Early results from a phase 1/2 study of Aru-1801 gene therapy for sickle cell disease (SCD): manufacturing process enhancements improve efficacy of a modified gamma globin … M Grimley, M Asnani, A Shrestha, S Felker, C Lutzko, PI Arumugam, ... Blood 136, 20-21, 2020 | 15 | 2020 |
| Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia ER Meier, SE Creary, MM Heeney, M Dong, AO Appiah-Kubi, SC Nelson, ... Trials 21, 1-14, 2020 | 14 | 2020 |
| Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia O Niss, J Detterich, JC Wood, TD Coates, P Malik, MD Taylor, CT Quinn Blood, The Journal of the American Society of Hematology 140 (11), 1322-1324, 2022 | 12 | 2022 |
| Lymphopenia in adults after the Fontan operation: prevalence and associations T Alsaied, M Possner, N Brown, H Almeneisi, C Szugye, AT Trout, O Niss, ... Cardiology in the Young 30 (5), 641-648, 2020 | 11 | 2020 |
